Adult Immunization

Latest News

FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited
FDA Approves Merck's 21-Valent Pneumococcal Vaccine for Adults 50 Years of Age and Older: A First and Long-Awaited

June 18th 2024

Capvaxive is the only pneumococcal vaccine formulated specifically to protect adults 50 years and older from IPD and elicited robust immune responses in both vaccine-naïve and vaccine-experienced adults.

©Kateryna_Kon/stock.adobe.com
Phase 3 Trial of Combination Flu/SARS-CoV-2 Vaccine Meets All Primary Endpoints: Moderna

June 11th 2024

FDA Approves GSK Vaccine Arexvy for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years
FDA Approves GSK Vaccine Arexvy for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years

June 7th 2024

FDA Approves First mRNA Vaccine Against RSV for Adults Aged ≥60 Years: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves First mRNA Vaccine Against RSV for Adults Aged ≥60 Years: Daily Dose

June 7th 2024

FDA Approves Moderna's mRESVIA, First mRNA Vaccine Against RSV, for Adults Aged ≥60 Years / image credit FDA approval ©Waldenmarus/stock.adobe.com
FDA Approves Moderna's mRESVIA, First mRNA Vaccine Against RSV, for Adults Aged ≥60 Years

June 3rd 2024

More News

© 2024 MJH Life Sciences

All rights reserved.